申请人:Hoffman-La Roche Inc.
公开号:US04472435A1
公开(公告)日:1984-09-18
There is presented novel benzophenone derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, R.sup.2 is hydrogen or aminoacetyl, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen or halogen, R.sup.5 is hydrogen, amino, nitro or a group of the formula R.sup.3 --ON.dbd.C(R.sup.6)--and R.sup.6 is lower alkyl, with the proviso that R.sup.5 is a group of the formula H--ON.dbd.C(R.sup.6)--when R.sup.2 and R.sup.3 are both hydrogen, and their pharmaceutically acceptable acid addition salts. The compounds exhibit aldosterone-antagonistic properties and are accordingly suitable for the control or prevention of heart failure, hepatic ascites, primary aldosteronism and idiopathic hypertension.
提供了一种新型苯酮衍生物,其化学式为##STR1##其中R.sup.1为氢或低碳基,R.sup.2为氢或氨基乙酰基,R.sup.3为氢或低碳基,R.sup.4为氢或卤素,R.sup.5为氢、氨基、硝基或具有化学式R.sup.3 --ON.dbd.C(R.sup.6)--的基团,而R.sup.6为低碳基,但R.sup.5为H--ON.dbd.C(R.sup.6)--基团当R.sup.2和R.sup.3均为氢时,以及它们的药用可接受的酸盐。这些化合物具有醛固酮拮抗性质,因此适用于控制或预防心力衰竭、肝性腹水、原发性醛固酮分泌过多症和特发性高血压。